Related Experiment Videos
Access to diagnostic methods for diffuse gliomas in adults in Argentina
Elias Ortega Chahla1, Natalia Gudiño2, Matías Agustín Atencio3
1Universidad de Buenos Aires.
Introduction:
Adult diffuse gliomas require molecular testing for accurate diagnosis and personalized treatment. In Argentina, access to these biomarkers is uneven, influenced by regional, institutional, and health coverage factors. Objectives: To analyze access to pathological and molecular diagnostic methods for adult diffuse gliomas in Argentina, identifying inequalities and barriers.
Methods:
Observational, descriptive, cross-sectional study based on a structured survey of 52 specialists (oncology, neurosurgery, pathology, radiotherapy) conducted between October–December 2024. Biomarker availability, healthcare coverage, and patient volume were assessed. Chi-square, Fisher, and Cochran-Armitage tests were applied.
Results:
The most available biomarkers were IDH1/2 non-canonical mutations and 1p/19q codeletion (67%), followed by ATRX/TP53 (62%) and IDH1 R132H (56%). Less available were EGFR and MGMT (44%), BRAF (40%), CDKN2A (23%), TERTp/H3K27M (14%), and Chr7/Chr10 (<10%). Availability was associated with province, workplace, specialty, and patient load. Patients without insurance reported lower access (mean 2.39/5) compared with those with insurance (3.35/5).
Conclusion:
Molecular diagnostics for adult diffuse gliomas in Argentina remain limited and uneven, with regional and institutional gaps affecting equity. Strengthening diagnostic infrastructure and public funding is essential to ensure precision oncology.